Arcellx, Inc.

Arcellx, Inc. (ACLX) priced its initial public offering on Feb 7, 2022 at $15.00 per share, within its $15.00–$17.00 range, raising $123.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $503.2M. BofA Securities was lead-left underwriter, joined by Leerink Partners, Barclays and William Blair. Wilson Sonsini advised the company and WilmerHale advised the underwriters.

Arcellx, Inc. is a clinical-stage biotechnology company developing cell therapy immunotherapies for cancer and other incurable diseases. Its approach centers on a synthetic binding scaffold called the D-Domain.

Status

IPO

Ticker

ACLX

Exchange

Nasdaq Global Select

Priced

Feb 7, 2022

IPO price

$15.00

Price range

$15.00–$17.00

Raised

$123.8M

Market cap at IPO price

$503.2M

First filed

Jan 14, 2022

Underwriters

BofA Securities, Leerink Partners, Barclays and William Blair

Company counsel

Wilson Sonsini

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.